Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Dec;143(7):819-26.
doi: 10.1038/sj.bjp.0706013. Epub 2004 Oct 18.

Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation

Paul Jurasz  1 , David Alonso-Escolano, Marek W Radomski
Affiliations
Review

Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation

Paul Jurasz et al. Br J Pharmacol. 2004 Dec.

Abstract

During haematogenous metastasis, cancer cells migrate to the vasculature and interact with platelets resulting in tumour cell-induced platelet aggregation (TCIPA). We review: 1. The biological and clinical significance of TCIPA; 2. Molecular mechanisms involved in platelet aggregation by cancer cells; 3. Strategies for pharmacological regulation of these interactions. We conclude that pharmacological regulation of platelet-cancer cell interactions may reduce the impact of TCIPA on cancer biology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Major mechanisms and pharmacology of TCIPA depicting the interactions between tumour cells, platelets, and endothelial cells. Mediators and antagonists of TCIPA are shown in blue and red, respectively. ASA, acetyl salicylic acid; COX-1, cyclooxygenase-1; GSNO, S-nitrosoglutathione, MMPIs, matrix metalloproteinase inhibitors; 2-MeSAMP, 2-methylthio-AMP; PGI2, prostacyclin; SNAP, S-nitroso-N-acetylpenicillamine; TF, tissue factor, vWF, von Willebrand factor.
See this image and copyright information in PMC

References

    1. ALONSO D., RADOMSKI M.W. Nitric oxide, platelet function, myocardial infarction and reperfusion therapies. Heart Fail. Rev. 2003;8:47–54. - PubMed
    1. ALONSO-ESCOLANO D., STRONGIN A.Y., CHUNG A.W., DERYUGINA E.I., RADOMSKI M.W. Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br. J. Pharmacol. 2004;141:241–252. - PMC - PubMed
    1. AMIRKHOSRAVI A., MOUSA S.A., AMAYA M., BLAYDES S., DESAI H., MEYER T., FRANCIS J.L. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb. Haemost. 2003;90:549–554. - PubMed
    1. BAKEWELL S.J., NESTOR P., PRASAD S., TOMASSON M.H., DOWLAND N., MEHROTRA M., SCARBOROUGH R., KANTER J., ABE K., PHILLIPS D., WEILBAECHER K.N. Platelet and osteoclast b3 integrins are critical for bone metastasis. Proc. Natl. Acad. Sci. U.S.A. 2003;100:14205–14210. - PMC - PubMed
    1. BANDO H., YAMASHITA T., TSUBURA E. Effects of antiplatelet agents on pulmonary metastases. Gann. 1984;75:284–291. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources